JP2003518064A5 - - Google Patents

Download PDF

Info

Publication number
JP2003518064A5
JP2003518064A5 JP2001546648A JP2001546648A JP2003518064A5 JP 2003518064 A5 JP2003518064 A5 JP 2003518064A5 JP 2001546648 A JP2001546648 A JP 2001546648A JP 2001546648 A JP2001546648 A JP 2001546648A JP 2003518064 A5 JP2003518064 A5 JP 2003518064A5
Authority
JP
Japan
Prior art keywords
compound
formula
substituted
chemical
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001546648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003518064A (ja
Filing date
Publication date
Priority claimed from US09/476,927 external-priority patent/US6387897B1/en
Application filed filed Critical
Publication of JP2003518064A publication Critical patent/JP2003518064A/ja
Publication of JP2003518064A5 publication Critical patent/JP2003518064A5/ja
Pending legal-status Critical Current

Links

Images

JP2001546648A 1999-12-20 2000-12-20 置換ピペラジンおよびピペリジンカルシウムチャネルブロッカー Pending JP2003518064A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17283199P 1999-12-20 1999-12-20
US60/172,831 1999-12-20
US09/476,927 1999-12-30
US09/476,927 US6387897B1 (en) 1998-06-30 1999-12-30 Preferentially substituted calcium channel blockers
PCT/CA2000/001557 WO2001045709A1 (en) 1999-12-20 2000-12-20 Substituted piperazine and piperidine calcium channel blockers

Publications (2)

Publication Number Publication Date
JP2003518064A JP2003518064A (ja) 2003-06-03
JP2003518064A5 true JP2003518064A5 (https=) 2009-08-27

Family

ID=26868504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001546648A Pending JP2003518064A (ja) 1999-12-20 2000-12-20 置換ピペラジンおよびピペリジンカルシウムチャネルブロッカー

Country Status (18)

Country Link
US (2) US6387897B1 (https=)
EP (1) EP1244451B1 (https=)
JP (1) JP2003518064A (https=)
KR (1) KR100823889B1 (https=)
CN (1) CN100477992C (https=)
AT (1) ATE333878T1 (https=)
AU (1) AU784206B2 (https=)
BR (1) BR0016530A (https=)
CA (1) CA2394327C (https=)
DE (1) DE60029634T2 (https=)
DK (1) DK1244451T3 (https=)
ES (1) ES2269220T3 (https=)
HK (1) HK1049969B (https=)
IL (1) IL150117A0 (https=)
MX (1) MXPA02006138A (https=)
NO (1) NO323724B1 (https=)
PT (1) PT1244451E (https=)
WO (1) WO2001045709A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951862B2 (en) * 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
WO2004089922A2 (en) * 1998-06-30 2004-10-21 Neuromed Technologies, Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6943168B2 (en) * 1998-06-30 2005-09-13 Neuromed Technologies Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US7186726B2 (en) * 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US6387897B1 (en) * 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US20060084660A1 (en) * 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
US20040266784A1 (en) * 1998-06-30 2004-12-30 Snutch Terrance P. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US20040259866A1 (en) * 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2003066040A1 (en) * 2002-02-05 2003-08-14 Ajinomoto Co.,Inc. Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
US20030199523A1 (en) * 2002-02-28 2003-10-23 Snutch Terrance P. Heterocyclic calcium in channel blockers
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
JP2006522742A (ja) * 2003-04-08 2006-10-05 ニューロームド テクノロジーズ、インク． ピペラジンから距離をおいて配置したベンズヒドリル基から成る一群のカルシウムチャンネル阻害剤
WO2004093816A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
US20060135506A1 (en) * 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
CN1816332A (zh) * 2003-05-30 2006-08-09 神经医药技术股份有限公司 3－氨基甲基－吡咯烷作为n－型钙通道阻断剂
WO2005015159A2 (en) * 2003-08-08 2005-02-17 The Regents Of The University Of California. Methods for modulating a drug-related effect or behavior
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7507760B2 (en) * 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
AU2005231872A1 (en) * 2004-04-09 2005-10-20 Neuromed Pharmaceuticals Ltd. Diarylamine derivatives as calcium channel blockers
US20050227999A1 (en) * 2004-04-09 2005-10-13 Neuromed Technologies Inc. Diarylamine derivatives as calcium channel blockers
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
MX2007002410A (es) 2004-08-30 2007-05-07 Neuromed Pharmaceuticals Ltd Derivados de urea como bloqueadores de canal de calcio.
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7511077B2 (en) 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
EP1871372A4 (en) * 2005-04-08 2010-06-02 Neuromed Pharmaceuticals Ltd COMBINATION THERAPY WHICH INCLUDES AN AGENT BLOCKING CALCIUM CHANNELS OF TYPE N FOR THE RELIEF OF PAIN
JP2009504637A (ja) * 2005-08-08 2009-02-05 アストラゼネカ・アクチエボラーグ 治療薬
US8299211B2 (en) * 2005-09-30 2012-10-30 The Board Of Trustees Of The University Of Illinois Peptides and regulation of calcium channels
WO2007041360A2 (en) * 2005-09-30 2007-04-12 The Board Of Trustees Of The University Of Illinois Peptides and calcium regulation in mammalian cells
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8937181B2 (en) * 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2007133481A2 (en) * 2006-05-11 2007-11-22 Neuromed Pharmaceuticals Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
US20100168103A1 (en) * 2006-09-14 2010-07-01 Neuromed Pharmaceuticals Ltd. Diaryl piperidine compounds as calcium channel blockers
CA2666275A1 (en) * 2006-10-13 2008-04-17 Neuromed Pharmaceuticals Ltd. Cyclopropyl-piperazine compounds as calcium channel blockers
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
ES2428326T3 (es) * 2007-10-04 2013-11-07 Merck Sharp & Dohme Corp. Derivados de aril sulfona sustituida como bloqueadores de canales de calcio
CA2702429A1 (en) * 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
US20090270413A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Di-t-butylphenyl piperazines as calcium channel blockers
WO2010036589A1 (en) * 2008-09-29 2010-04-01 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
ES2598178T5 (es) 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
EP2352501B1 (en) * 2008-11-03 2014-01-01 ChemoCentryx, Inc. Compounds for use in the treatment of osteoporosis
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
CA2812109A1 (en) 2010-09-20 2012-03-29 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia
EP2654726A1 (en) 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2961403A4 (en) 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
US10168144B2 (en) 2016-03-25 2019-01-01 Sony Corporation Optical apparatus for 3D data collection

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051527A (https=) 1964-07-31
US3997539A (en) 1974-05-31 1976-12-14 American Hoechst Corporation 3-(4-Acylaminopiperazin-1-yl alkyl)indoles, precursors and processes for the preparation thereof
US4188485A (en) 1978-06-16 1980-02-12 G. D. Searle & Co. 1-[(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)methyl]-4-substituted piperidines and related compounds
JPS61155358A (ja) 1984-12-21 1986-07-15 Suntory Ltd ジアリール酪酸誘導体
FR2584723B1 (fr) 1985-07-09 1988-02-12 Adir Nouveaux derives du dihydro-2,3 benzofuranne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
DE3600390A1 (de) 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
US5386025A (en) 1990-02-20 1995-01-31 The Salk Institute Biotechnology/Industrial Associates Calcium channel compositions and methods
IE73232B1 (en) 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
US5703071A (en) 1990-08-29 1997-12-30 Pharmacia & Upjohn Company Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
DE4111861A1 (de) 1991-04-11 1992-10-15 Schwabe Willmar Gmbh & Co Benzopyranone, verfahren zu ihrer herstellung und verwendung
AU5833494A (en) 1992-12-22 1994-07-19 Smithkline Beecham Plc Piperidine derivatives as calcium channel antagonists
CA2153979C (en) 1993-12-08 2003-10-21 Mark Hellberg Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
US5623051A (en) 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
AU730364B2 (en) 1997-09-23 2001-03-08 Bristol-Myers Squibb Company Selective cPLA2 inhibitors
IL135488A0 (en) 1997-11-18 2001-05-20 Teijin Ltd Cyclic amine derivatives
US6387897B1 (en) * 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
US6267945B1 (en) 1998-12-18 2001-07-31 Neuromed Technologies, Inc. Farnesol-related calcium channel blockers

Similar Documents

Publication Publication Date Title
JP2003518064A5 (https=)
SI1663197T1 (sl) Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
US6387897B1 (en) Preferentially substituted calcium channel blockers
CA2206776C (en) N-sulfonylindoline derivatives carrying an amide functional group, their preparation and the pharmaceutical compositions in which they are present
US7064128B2 (en) Preferentially substituted calcium channel blockers
CA2530374C (en) Hsp90 family protein inhibitors
CA2429844A1 (en) Mch antagonists and their use in the treatment of obesity
MY136034A (en) New medicaments for the treatment of chronic obstructive pulmonary disease
RU2003128992A (ru) Омега-аминоалкиламиды r-2-арилпропионовых кислот в качестве ингибиторов хемотаксиса полиморфноядерных и одноядерных клеток
BRPI0412219A (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para regular a transdução de sinal método para tratamento ou prevenção de uma doença
NO20024042D0 (no) Aryl-fusjonerte azapolysykliske forbindelser
MXPA06002296A (es) Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
RU2010137115A (ru) Производные 5,6-бисарил-2-пиридинкарбоксамидов, способ их получения и их применение в терапии в качестве антагонистов рецепторов
DK1270570T3 (da) Amidforbindelser og anvendelse deraf
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
CN102164887A (zh) 抗纤维化剂的卤代类似物
JPH10287651A5 (https=)
JP2005517665A5 (https=)
EP0233762B1 (en) Use of aromatic diamines for the treatment of angina pectoris, and diamines therefor
WO2024226819A3 (en) Ibogaine and noribogaine analogs and methods of use
KR101555626B1 (ko) 신경병성 통증에 활성이 있는 약물
HUT57740A (en) Process for producing n-arylpiperazine alkaneamide derivatives of general formula (i) and pharmaceutical compositions promoting sleep and comprising such compounds
DK173807B1 (da) Fremgangsmåde til fremstilling af dihydropyridin-derivater
EP1253139A3 (en) Multioligoanilinated fullerenes
JP2007536240A5 (https=)